Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02632656 · ClinicalTrials.gov registry record

Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study

A clinical trial of Congestive Heart Failure, sponsored by Massachusetts General Hospital.

Active
Registry status
400
Enrollment target
1
Study location

NCT02632656: Active study of Congestive Heart Failure, sponsored by Massachusetts General Hospital.

NCT02632656 is a study of Congestive Heart Failure that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 400 participants, above the 322-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (24% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02632656, a study of Congestive Heart Failure, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
400 participants
Enrollment target
1
Study location

Study Summary

The primary objective is to measure the association between extracellular RNA (ex-RNA) levels in plasma in patients receiving aggressive outpatient therapy for CHF with (1) cardiac remodeling and (2) cardiovascular events. The investigators will follow patients during standard medical therapy for CHF to assess changes in ex-RNA levels in the plasma, and how these are associated with cardiac remodeling (by cardiac imaging) and outcomes.

Conditions Studied

Interventions

  • OTHER Monitoring on heart failure therapy

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2015-12
Est. Completion 2026-12-01
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT02632656 still lists

NCT02632656 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 322-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (24% higher).

The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Monitoring on heart failure therapy is the first listed.

NCT02632656 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02632656 about?

NCT02632656 is a clinical study titled "Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study". The primary objective is to measure the association between extracellular RNA (ex-RNA) levels in plasma in patients receiving aggressive outpatient therapy for CHF with (1) cardiac remodeling and (2) cardiovascular events. The investigators will follow patients during standard medical therapy for CH...

What is the current status of trial NCT02632656?

This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2015-12. Estimated completion is 2026-12-01.

What conditions does trial NCT02632656 study?

This clinical trial studies the following conditions: Congestive Heart Failure.

What interventions are being tested in trial NCT02632656?

The interventions under investigation include: Monitoring on heart failure therapy (OTHER).

Who is sponsoring clinical trial NCT02632656?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02632656 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congestive Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02632656's enrollment target sits among peer trials

400 10th of 51 higher than 42 of 51 other Congestive Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Congestive Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02632656, the US trial registry maintained by the National Library of Medicine. NCT02632656 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.